RAPIBLOC 300 mg, poudre pour solution pour perfusion
APHP191047
Phase 3 small_molecule active
Quick answer
RAPIBLOC 300 mg, poudre pour solution pour perfusion for Patients with microcirculatory abnormalities during septic shock is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Patients with microcirculatory abnormalities during septic shock
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active